

PATENT
ATTORNEY DOCKET NO. 044137-5025-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Continued Prosecution Application of:

Alan SOLOMON *et al.*

Application No.: 09/316,387

Filed: May 21, 1999

For: METHODS FOR AMYLOID REMOVAL
USING ANTI-AYLOID ANTIBODIES

Group Art Unit: 1647

Examiner: S. Turner

Commissioner for Patents
U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Sir:

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above referenced application.

Copies of the listed documents were submitted with the response filed on October 23, 2002 and therefore are not attached here. Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that any of the listed documents do not

#23
SQJ
7/15/03

Attorney Docket No. 044137-5025-01
Application No.: 09/316,387
Page 2


constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP


Sally P. Teng
Reg. No. 45,397

Dated: June 27, 2003

Customer No. 09629
MORGAN, LEWIS & BOCKIUS LLP
1111 Pennsylvania Avenue, N.E.
Washington, D.C. 20004
(202) 739-3000

FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office		Atty. Dkt. No.	Client/Matter No.	Client Ref.		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		044137-5025-01				
		Applicant: Alan SOLOMON <i>et al.</i>				
		Appln. No.: 09/318,387				
		Filing Date: May 21, 1999				
Date:	Page 1 of 1	Examiner: S. Turner	Group Art Unit: 1647			
U.S. PATENT DOCUMENTS						
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR						
BR						
CR						
DR						
ER						
FOREIGN PATENT DOCUMENTS					English Abstract	Translation Readily Available
	Document Number	Date MM/YYYY	Country	Inventor Name	Enclosed	No
FR						
GR						
HR						
IR						
JR						
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)						
KR	Holmgren <i>et al.</i> , Lancet, Vol. 341, May 1, 1993, pp. 1113-1116					
LR	Kun <i>et al.</i> , "Water-soluble A β (N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains", The Journal of Biological Chemistry, Vol. 271, No. 8, Feb. 23, 1996, pp. 4077-4081					
MR	Schehr, "Therapeutic Approaches to Alzheimer's Disease", Bio/Technology, Vol. 12, Feb. 1994, pp. 140-144					
NR	Grubeck-Lobenstein <i>et al.</i> , "Immunization with β -amyloid: could T-cell activation have a harmful effect?", TINS, Vol. 23, No. 3, 2000, pp. 11					
OR	Lee, "A β immunization: Moving A β peptide from brain to blood", PNAS, Vol. 98, No. 16, July 31, 2001, pp. 8931-8932					
PR	Shenk <i>et al.</i> , "Immunization with amyloid- β attenuates Alzheimer-disease-like pathology in the PDAPP mouse", Nature, Vol. 400, July 8, 1999, pp. 173-177					
QR	Falk <i>et al.</i> , "The Systemic Amyloidoses", The New England Journal of Medicine, Vol. 337, No. 13, Sept. 25, 1997, pp. 890-908					
RR	Tjernberg <i>et al.</i> , "Arrest of β -Amyloid Fibril Formation by a Pentapeptide Ligand", The Journal of Biological Chemistry, Vol. 271, No. 15, April 12, 1996, pp. 8545-8548					
SR	Kisilevsky, "Anti-Amyloid Drugs - Potential in the Treatment of Diseases Associated with Aging", Drugs & Aging, Vol. 8, No. 2, Feb., 1996, pp. 75-83					
TR						
Examiner				Date Considered:		
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 600. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.						